

topical reviews
Preparing for successful protein crystallization experiments
aUniversity at Buffalo Hauptman Woodward Institute, Buffalo, NY 14203, USA, bDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Science, University
at Buffalo, Buffalo, NY 14203, USA, and cNational Synchrotron Light Source II, Brookhaven National Laboratory, Upton, NY 11973,
USA
*Correspondence e-mail: [email protected]
Crystal-based structural methods, including X-ray crystallography, are frequently utilized for the determination of high-resolution structures of biomolecules. All crystal-based diffraction methods first require the preparation of biomolecular crystals, and careful sample preparation for crystallization experiments can increase the frequency of success. In this article, strategies to optimize factors that can impact crystallization are presented, from which buffers and reducing agents are most favorable to which crystallization techniques could be used.
Keywords: crystallization; X-ray crystallography; structural biology; X-ray free-electron lasers; electron diffraction.
1. Introduction: what is crystallization?
Crystallization is the first step in performing any crystal-based diffraction experiment.
Close to 85% of all biomolecular structural models deposited in the Protein Data Bank
(PDB) are from crystal-based experiments (Budziszewski et al., 2023), highlighting the importance of crystallization as a method. At its core, biomolecular
crystallization is a process in which crystals grow from a thermodynamically metastable
or supersaturated solution via a phase-separation process. Crystallization of biomolecules
requires a balance between stabilizing and solubilizing the sample coupled with driving
toward an ordered aggregate, resulting in a lattice held together by a periodic network
of sparse and weak intermolecular interactions. For biomolecules, crystallization
often proceeds through extensive experimentation, but there are guiding principles
that can be employed to increase the chance of success. There is an extensive history
of literature that describes methods to crystallize biomolecules (Luft et al., 2001
; Dale et al., 2003
; Bergfors, 2009
; McPherson & Gavira, 2014
; Rosa et al., 2020
; Lynch et al., 2023
). Here, we build upon that literature to discuss specific features of sample preparation
that should be considered prior to biomolecular crystallization experiments, as described
during the workshop entitled SAMPREP (Sample Attributes for Multiple techniques and
Principal Requirements for Experiments in Pan-structural biology) presented during
the 73rd Annual American Crystallographic Association Meeting in July 2023.
2. Biochemical considerations
There are a wide variety of biochemical parameters to consider when preparing a sample
for crystallization experiments. Firstly, a high level of purity (typically >95%)
is needed for biomolecules to crystallize. Methods to investigate the purity of samples
used in structural studies have been discussed (Liu et al., 2020). Sources of impurities and heterogeneity that may impact crystallization include
isoforms, flexible regions, disordered regions, misfolded populations, partial proteolysis,
cysteine oxidation and deamidation of Asn and Gln residues to Asp and Glu residues.
Additional biochemical considerations include the presence or absence of glycosylation
or post-translational modifications. If crystals do form in the presence of impurities,
the result is often poor diffraction due to a disordered crystal lattice.
Secondly, the biomolecular sample needs to be very stable for crystallization, as
crystals can take an extended time (days to months) to nucleate. Components to consider
to maintain sample stability include buffers, salts, glycerol and substrates for soluble
proteins, in addition to detergents, micelles or nanodiscs for membrane proteins.
Ideally, buffer components should be kept below ∼25 mM concentration and salt components (i.e. sodium chloride) should be kept below 200 mM concentration. Phosphate buffers should be avoided, as they easily form insoluble
salts. Some samples will require addition of substrate, ligand, coordinating metal
or reductant to the sample buffer to keep the biomolecule stable. When using chemical
reductants during crystallization, reductant lifetime should be considered in the
context of the timescale for crystal growth (Table 1). Methods such as differential scanning fluorimetry and can be used to assess the stability of the sample as a function of buffer component
to identify the most suitable buffer, salt and pH, as well as to investigate the impact
of temperature and the presence of ligands or stabilizing chemicals on stability.
The ideal pH is one at which the sample is stable, as surface charges can affect crystal
packing. Note that the crystallization cocktail (see below) is also pH dependent,
and pH is a common cocktail parameter to vary during crystallization optimization.
|
Thirdly, a highly soluble, homogeneous sample is usually required for optimal crystallization experiments. A number of approaches are appropriate to assess sample v/v) in the final crystallization drop. The best sample buffer to use in crystallization trials is the simplest formulation that will maintain sample stability, solubility and activity. Once the best conditions have been determined for the sample, crystallization experiments can proceed.
and solubility, including dynamic (DLS), (SEC), coupled with multi-angle (SEC-MALS) and mass photometry. An ideal sample for crystallization will be monodisperse and not prone to aggregation. Glycerol is often needed for sample solubilization. Practically speaking, for crystallization trials glycerol should be kept to below 5%(All of the considerations above can be, in part, addressed by carefully considering
construct design prior to, or iteratively with, crystallization screening. Once the
structural objective has been honed, constructs can be analyzed for stability and
crystallization propensity (Slabinski et al., 2007). Flexible regions are generally unfavorable to crystallization, as they induce conformational
heterogeneity. AlphaFold3 is an excellent resource to guide construct design and eliminate floppy regions
that may interfere with crystallization (Abramson et al., 2024
). Affinity tags can improve the solubility properties of some proteins and act as
crystallization chaperones (Smyth et al., 2003
; Tamura et al., 2019
; Nawarathnage et al., 2023
) and may be worthwhile pursuing in challenging cases. Biomolecules that continue
to prove recalcitrant to crystallization may also be resurfaced to improve crystal
contacts (Derewenda & Vekilov, 2006
; Liu et al., 2007
; Banayan et al., 2024
), but care should be taken to validate that mutations do not broadly disrupt structure
or function in a way that can invalidate conclusions from structural data.
3. Physical considerations
Crystallization typically occurs in the presence of a cocktail of chemical components
that promote crystal formation (often referred to as the crystallization cocktail
or mother liquor). These chemical mixtures are designed to modulate the solubility
of biomolecules. A crystallization cocktail that promotes productive crystal formation
will cause the sample to traverse the phase diagram from the undersaturated phase
into the nucleation and metastable phases (Fig. 1). Crystallization conditions are generally composed of some combination of buffers
to mediate pH, salts, polymers and additives. Crystallization of biomolecules remains
primarily determined empirically, so many trials of crystallization conditions may
be required to find a suitable condition to induce crystal growth. As a starting point,
crystallization conditions for homologous proteins can be extracted from the PDB.
While efforts have been made to mine the data in the PDB to generate predictive algorithms
for protein crystallization (Lynch et al., 2020
; Abrahams & Newman, 2019
), often an empirical approach proves to be necessary. Furthermore, crystallization
components can impact features of the including crystalline order, solvent content and which are key considerations for the diffraction experiment and downstream structural
interpretation.
![]() |
Figure 1 A phase diagram for biomolecular crystallization, with the sample concentration on the y axis and crystallization precipitant (cocktail) on the x axis. Different methods of crystallization can be utilized to assist biomolecular crystal nucleation, followed by stabilization in the metastable zone suitable for structural studies. |
One mechanism by which crystallization components influence biomolecule solubility
is through the salting-out phenomenon (McPherson, 2001; Finet et al., 2003
). Up to a certain salt concentration, salt molecules will enhance biomolecule stability
by generating electrostatic contacts with the protein surface. However, when salt
concentrations rise past a certain threshold, salts begin to compete with the biomolecule
for access to water molecules, forcing biomolecules to favor the weaker intermolecular
interactions that lead to lattice formation and crystal packing. The concentration
of salt at which salting-out occurs is biomolecule- and salt-dependent. Ammonium sulfate
is one commonly used salt for protein crystallization (Dumetz et al., 2007
), so much so that ammonium sulfate screens are offered by major crystallization screen
suppliers. Salts are common crystallization condition components, and participate
not only in reducing biomolecule solubility, but also in binding to biomolecules as
active ligands, particularly in the case of metal salts, as well as mediating intermolecular
interactions between biomolecules in the crystal lattice.
Polymers are another commonly used crystallization component, and serve several functions
that can promote the crystallization of biomolecules (Finet et al., 2003; Anderson et al., 2006
; Lynch et al., 2020
). One function is to screen salt-mediated aggregation at high salt concentrations
that may lead to unproductive precipitation of biomolecules (Ray & Puvathingal, 1986
). Polymers, such as high-molecular-weight polyethylene (PEGs), are also thought to induce macromolecular crowding (Lynch et al., 2020
; Rastogi & Chowdhury, 2021
; Liebau et al., 2024
), increasing the likelihood of biomolecules encountering one another in solution
in a manner befitting an ordered lattice. Viscosity could play a role in reducing
the entropic motion of biomolecules, perhaps lowering the barrier to formation. Polymers and some salts at significant concentrations also serve as cryoprotectant
molecules, promoting the formation of vitreous ice during cryocooling crystals.
Buffers to control the pH of the crystallization condition are often desirable, as
biomolecules frequently prefer to crystallize within 1–2 pH units of their pI (Kantardjieff
& Rupp, 2004). The pH of the solution impacts the ionization state of ionizable amino acids, which
can promote or antagonize intermolecular interactions. Additives that promote biomolecule
stability are generally beneficial, and may influence the ordering of floppy regions
of biomolecules or mediate intermolecular interactions required for lattice formation.
Additives are often key to inducing biomolecular crystallization. The most common
additive is 2-methyl-2,4-pentanediol (MPD), which binds to hydrophobic protein regions
and affects the overall hydration shell of the biomolecule (Anand et al., 2002). Useful additives may also include cofactors, substrate molecules, nonhydrolyzable
substrates, small molecules, partner proteins and Fab fragments that bind the target
biomolecule (Hoeppner et al., 2013
; Griffin & Lawson, 2011
; McPherson & Cudney, 2006
; Lieberman et al., 2011
).
Another key consideration for biomolecular crystallization is the concentration of
the biomolecule in solution when conducting crystallization screening. If we consult
the phase diagram (Fig. 1), there is a theoretical region where despite modulating the precipitant concentration,
there is no change in phase because the sample is not adequately concentrated. Similarly,
biomolecules can be overly concentrated and yield only precipitation during crystallization
screening efforts rather than productive nucleation and crystal growth. Therefore,
biomolecule concentration should be carefully considered before conducting large-scale
crystallization screening.
Biomolecules for crystallization should be highly pure (>95%) and homogenous in their stabilizing solution. Care must be taken not to concentrate the sample beyond the limits of solubility, at which soluble and insoluble aggregates can form, interfering with the crystallization process. Useful methods for assessing the
of a protein solution include native gel DLS and SEC-MALS.To assess whether the sample concentration is appropriate, a pre-crystallization test
based on the sparse-matrix crystallization approach is useful (Jancarik & Kim, 1991). The results of a hanging-drop crystallization experiment with four crystallization
cocktails serve as a guide to achieving a productive concentration of biomolecule
for crystallization. In rare cases experienced by the authors, pre-crystallization
testing leads directly to the growth of well diffracting protein crystals!
Finding appropriate crystallization conditions remains the primary bottleneck in crystal-based
structural determination methods, and therefore the likelihood of success is increased
as more conditions are tested (Lynch et al., 2023). The chemical space of crystallization cocktails is vast, and approaches to screen
this space most effectively have been developed. These approaches include the incomplete
factorial (Carter & Carter, 1979
), where key drivers of crystallization are identified by limited combinations of
multiple variables, and the sparse-matrix approach (Jancarik & Kim, 1991
), which includes conditions which have previously been successful in crystallizing
biomolecules. Many commercial screens now exist for both general biomolecular crystallization
and more specialized applications, including membrane proteins, and nucleic acid complexes, and protein–ligand complexes.
Interpretation of crystallization results from screening can yield more than just
positive crystallization results (`hits') and different crystal-based methods have
different optimal crystal sizes and shapes. Most would consider a well formed single
macrocrystal an excellent result of the screening process (Fig. 2). However, outcomes such as precipitation, spherulite formation, needles, plates and microcrystals can be analyzed to gain knowledge
about the phase behavior of the sample during crystallization experiments, as all
represent a point on the phase diagram. Several imaging methods, including the use
of UV–Vis, UV two-photon excited fluorescence (UV-TPEF) and second-harmonic generation
techniques (second-order nonlinear imaging of chiral crystals; SONICC), are available
to assist in the identification of protein crystals (Fig. 3
; Haupert & Simpson, 2011
; Lynch et al., 2023
). It should be noted that some macromolecules, including and metalloproteins, can sometimes quench the UV signal, which can lead to the dismissal
of macromolecular crystals as salt if care is not taken.
![]() |
Figure 2 A rainbow of brightfield images of several successful crystallization `hits' as examples (a scale bar is shown to the lower right of each image). |
![]() |
Figure 3 Example of five crystallization wells shown with brightfield (left), UV-TPEF (middle) and second-harmonic generation (SHG) SONICC images of successful crystallization screening using different types of imaging modalities. Even when protein crystals are obscured by precipitate, UV-TPEF and SHG images can assist with the identification of potentially promising crystal hits. These imaging methods also assist with the identification of microcrystals and nanocrystals. |
Most crystallization hits require some optimization to achieve adequate crystal size,
morphology and diffraction properties. Generally, optimization is conducted by iterative
grid screening, wherein two chemical variables are chosen to vary above and below
the hit condition concentration such that the local chemical space is well defined.
Some of these variables include precipitant concentration, pH, salt concentration
and additives. Additionally, the crystallization format may be altered, which influences
the path through the phase diagram by which crystallization is achieved (Fig. 1). It can also be helpful to use multiple drop volume ratios of macromolecule:cocktail
when optimizing conditions. Often when the format or drop size is altered conditions
need to be optimized to accommodate the change. Finally, altering the temperature
at which the experiment is incubated can influence both protein solubility and slow
crystallization kinetics, as lowering the incubation temperature can sometimes resolve
problems such as crystallization defects caused by rapid growth at higher temperatures.
The most commonly used temperatures for protein crystallization are 277, 298 and 293 K
(Lynch et al., 2020
).
Importantly, crystal quality is not always directly correlated with appearance in
the drop. Many crystallographers have experienced the heartbreak of a beautiful crystal
that does not diffract or the thrill of an ugly duckling that yields a high-quality
diffraction data set. The results of the diffraction experiment provide information
to guide the experimenter in further optimization. Some crystal pathologies can be
resolved by altering the crystallization conditions or incubation temperature, but
occasionally a condition results in a dead end where no further optimization can improve
the crystal quality or diffraction properties. In these cases, it is appropriate to
move on from these conditions or even reconsider the original biomolecular construct.
Construct factors such as adding or removing affinity tags (Kuge et al., 1997; Saul et al., 1998
; Chun et al., 2012
; Zou et al., 2012
), removing flexible regions, engineering short linkers between complex components
(Aÿ et al., 1998
) or resurfacing the biomolecule (Derewenda, 2004
; Banayan et al., 2024
) can be considered at the discretion of the experimenter.
4. Crystallization methods
Vapor diffusion is one of the primary methods used in macromolecular crystallization
experiments. In vapor diffusion, the macromolecule is combined with the crystallization
cocktail and then sealed in a well with a reservoir of the cocktail (Fig. 4a). Vapor diffusion can be set up in a sitting-drop format or a hanging-drop format;
in both cases the drops slowly dehydrate as water vapor diffuses from the drop to
the reservoir (Benvenuti & Mangani, 2007
). Microbatch-under-oil, another technique that is commonly used, depends on combining
the macromolecule and cocktail in a drop under paraffin or mineral oil (Fig. 4
b; Chayen et al., 1992
). Various plate types are available for setting up drops either manually or using
robotics. Robotic liquid-handling instrumentation can assist with drop setup with
very small volumes, from 25 to 200 nl, making efficient use of precious and hard-to-prepare
biomolecular samples. In plates with two or more drops, the macromolecule:cocktail
ratio can be set at various values. Studies have also been performed to compare crystallization
outcomes between vapor diffusion and microbatch-under-oil (Chayen, 1998
). Selecting the appropriate crystallization technique is sample-dependent and sometimes
involves trial and error.
![]() |
Figure 4 Different methods of crystallization experiment setup include (a) vapor diffusion and (b) microbatch-under-oil. |
There are additional methods of crystallization, including batch (Chayen et al., 1990; D'Arcy et al., 1996
), dialysis (Zeppezauer, 1971
; Thomas et al., 1989
) and other specialized methods. Recently even electromagnetic fields (Frontana-Uribe
& Moreno, 2008
) have been effectively used to control and manipulate the crystallization process.
Electric fields affect the force field between protein molecules, influencing the
nucleation process and the quality of the resulting crystals. Following the initial
paper by Taleb et al. (1999
), several studies have addressed various strategies to control the kinetics and transport
phenomena in the crystallization process. The method takes advantage of the batch
crystallization method, positioning the electrodes in contact with the protein solution
(for a recent review, see Alexander & Radacsi, 2019
). Despite the observed nucleation reduction and crystal quality improvement, this
method has some challenges: the batch method requires significant availability of
pure protein, and a dedicated device that combines the batch method with electric
fields is lacking. Rubin and coworkers combined the microbatch method (Chayen et al., 1992
) with a device that permitted the discretionary application of DC electric fields.
The device used by these authors is depicted in Fig. 5
; five microbatch crystallization plates (Hampton Research) are prepared simultaneously
under exactly the same conditions. Four plates, one each, are inserted between the
two electrodes available on each port and submitted to 1, 2.3, 4.1 and 6 kV. The fifth
plate is used as control and is not exposed to an electric field (Rubin et al., 2017
). Although high-quality large (>100 µm) to small (<5 µm) crystals were obtained,
the use of electric or even magnetic fields for protein crystallization is challenging
and has not been widely used or implemented. There are two major challenges. One is
the perception that large amounts of protein are required; with the availability of
current crystallization robots the quantities needed are greatly reduced. Secondly,
and probably the most important, is the lack of standard devices; a large variety
of `homemade' devices with diverse geometry can be encountered in the literature.
These factors are further compounded with lack of proper simulations, and therefore
our understanding of the molecular interactions and the electric field are limited.
![]() |
Figure 5 Microbatch crystallization in an electric field. (a) Overview of the electric field device used with microbatch plates showing the four `ports' available for DC voltage application: top right, port in closed configuration; bottom right, port in open configuration. (b) Open `port' showing the leads and microbatch plate ready for insertion between leads. |
Integral membrane proteins have long been considered highly challenging to crystallize,
as a result of significant tracts of hydrophobic membrane-interacting residues which
make these proteins challenging to stabilize in a purely aqueous solution. Efforts
to stabilize integral membrane proteins for crystallization by introducing exogenous
; Nikolaev et al., 2017
; Shelby et al., 2020
). Additionally, lipidic cubic phase crystallization, involving a mixture of and water that generates a liquid-crystal array studded with aqueous channels, has
also been implemented in the last 30 years and is now facilitated by liquid-handling
robots (Landau & Rosenbusch, 1996
; Caffrey, 2015
; Cherezov, 2011
). Other methods of crystallizing membrane proteins include the use of styrene–maleic
acid copolymers, which obviate the need to use solubilizing detergents at all (Broecker
et al., 2017
).
Seeding methods, particularly matrix microseeding (Shaw Stewart et al., 2011; D'Arcy et al., 2014
), can be useful for improving the quality of subpar crystals or generating highly
reproducible crystallizations. In this approach, parent crystals are fragmented and
then included in iterative screening to reduce the entropic barrier to crystallization
by providing pre-formed nucleation sites. Usefully, cross-seeding approaches can be
employed wherein the parent seeds are obtained from a closely related, but not identical,
molecule that has previously been crystallized (Caspy et al., 2025
). Several rounds of seeding can be conducted to achieve a desirable outcome and seeds
can be stored to repeat crystal-growth experiments in the future.
5. Future outlook for crystal-based structural biology
The growth of competing and complementary experimental structural techniques, including both single-particle cryo-electron microscopy (cryo-EM) and the advent of highly accurate protein structure prediction, have altered the scope of biomolecular crystallography projects. Because of the bottleneck in finding appropriate crystallization conditions, structural solutions by crystallographic methods can be somewhat elusive for uncharacterized systems, making both structure prediction and alternative methods appealing. However, crystal-based structural methods have and will continue to play a key role in structural solution and analysis because of a few major strengths of the technique.
In drug-discovery efforts, ligand-bound structures are desirable to understand the
mechanism by which a ligand binds to influence the function of a biomolecule. Understanding
ligand-bound structures can also lend support to rational drug-design campaigns (Zheng
et al., 2014; Mazzorana et al., 2020
). Another key tool for rational drug-design efforts are fragment-based screens, in
which crystals of a target protein are grown or soaked in the presence of small-molecule
moieties that represent pieces of a larger final scaffold (Murray & Rees, 2009
; Erlanson et al., 2016
). X-ray crystallography is well suited to capture the low-affinity binding events
with which these fragments bind to biomolecules that may go undetected using common
biophysical screening assays, and inform directly on the mechanism of interaction
of the fragment, as well as its occupancy in the structure. Advances in robotics,
liquid handling and the throughput of synchrotron sources make fragment-based screening
a tenable option that is especially well suited for hard-to-target biomolecules. Although
it is possible to determine ligand-bound structures with single-particle cryo-EM,
it is not high throughput and often lacks the appropriate resolution to unambiguously
define a binding event. Additionally, the averaging of particles necessary to solve
a structure by single-particle cryo-EM makes it unlikely that partial occupancy ligands
will be identified as routinely as with crystal-based methods. These limitations in
cryo-EM are beginning to be addressed with new methods (Muenks et al., 2023
). The computational structure-prediction model AlphaFold3 is now capable of predicting the structure of biomolecules bound to ligands, promising
to accelerate drug-discovery hypotheses (Abramson et al., 2024
). For the time being, however, experimental structures, primarily solved using X-ray
crystallography, are the gold standard for defining protein–ligand interactions and
testing hypothetical models generated by predictive methods.
Several emerging technologies capitalize on the use of microcrystals and nanocrystals,
which were previously limited in their utility for diffraction experiments (Kupitz,
Grotjohann et al., 2014; Shoeman et al., 2023
). Microfocus beams (on the order of 1 × 1.5 µm) enable the collection of data from
very small crystal samples at synchrotron sources. Small-sized crystal samples have
proven to be optimal for interrogation by X-ray free-electron lasers (XFELs) and in
serial synchrotron experiments, where single diffraction images are collected from
many individual crystals to provide a complete data set (Kern et al., 2013
; Kupitz, Basu et al., 2014
; Pearson & Mehrabi, 2020
). Electron diffraction methods offer an additional emerging strategy to collect structural
information from nanoscale (100–600 nm) macromolecular crystals that were previously
intractable by X-ray-based methods (Nannenga & Gonen, 2019
). At VMXm at Diamond Light Source, crystals are mounted on EM grids within a vacuum
chamber to minimize background scatter from air at the synchrotron (Warren et al., 2024
). Pipelines are also being developed for crystals at room temperature, allowing structural
investigation of challenging fragile crystals and time-resolved studies (Mikolajek
et al., 2023
). Advances at XFELs using pulsed high-intensity X-ray beams allow structural determination
prior to radiation damage, which is especially important for metalloproteins (Hough
& Owen, 2021
).
XFEL and synchrotron-based X-ray diffraction experiments are also increasingly being
employed to study the dynamics of a sample in crystallo by perturbing the sample and observing time-resolved effects, enabling the investigation
of the structure of biomolecules in action (Lin et al., 2024; Smith et al., 2024
). Time-resolved structural experiments represent the frontier of structural biology
in understanding the interplay of structure and function and promise to inform on
key mechanistic details of biochemical reactions. Critical for all of these dynamic
and time-resolved studies is the sample size; therefore, much time has been invested
in obtaining uniformly sized microcrystals and nanocrystals. All of these cutting-edge
structural methods make it possible to use nearly the entire range of potential crystal
sizes to collect structural information, making crystal-based methods a more powerful
and versatile tool than ever, fit to answer many of the questions posed by modern
structural biology.
6. Concluding thoughts
Sample preparation is a critical part of generating crystals for structural biology.
It can often take some trial and error to find the correct sample construct, the optimal
crystallization cocktail and the best method of crystallization. When confronting
difficulties in crystallizing biomolecules, we recommend asking advice from experienced
groups or facility staff, especially for new crystallographers. Facilities are also
available to provide access to both expertise and to a wide range of crystallization
reagents, plate types and robotics (Stegmann et al., 2023; Budziszewski et al., 2023
; Sandy et al., 2024
).
Supporting information
Video interview with the authors. DOI: https://doi.org/10.1107/S2053230X25004650/oq5003sup1.mp4
Acknowledgements
We gratefully acknowledge assistance with figure generation from Tiffany R. Wright, as well as Crystallization Center users, whose samples provided example images of crystals in Figs. 2 and 3. Some figures have utilized artwork created with Biorender.com and some figures have made use of Inkscape. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH.
Funding information
The National Crystallization Center at UB HWI is supported by the National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (R24GM141256). The Center of Biomolecular Structure (CBMS) is supported in part by NIH–NIGMS P30GM133893 and by the DOE Office of Biological and Environmental Research FWP
BO070 and NSLS-II is supported by DOE Office of Basic Energy Sciences Program under contract No. DE-SC0012704.References
Abrahams, G. J. & Newman, J. (2019). Acta Cryst. F75, 184–192. Web of Science CrossRef IUCr Journals Google Scholar
Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger,
O., Willmore, L., Ballard, A. J., Bambrick, J., Bodenstein, S. W., Evans, D. A., Hung,
C.-C., O'Neill, M., Reiman, D., Tunyasuvunakool, K., Wu, Z., Žemgulytė, A., Arvaniti,
E., Beattie, C., Bertolli, O., Bridgland, A., Cherepanov, A., Congreve, M., Cowen-Rivers,
A. I., Cowie, A., Figurnov, M., Fuchs, F. B., Gladman, H., Jain, R., Khan, Y. A.,
Low, C. M. R., Perlin, K., Potapenko, A., Savy, P., Singh, S., Stecula, A., Thillaisundaram,
A., Tong, C., Yakneen, S., Zhong, E. D., Zielinski, M., Žídek, A., Bapst, V., Kohli,
P., Jaderberg, M., Hassabis, D. & Jumper, J. M. (2024). Nature, 630, 493–500. Web of Science CrossRef CAS PubMed Google Scholar
Alexander, L. F. & Radacsi, N. (2019). CrystEngComm, 21, 5014–5031. Web of Science CrossRef CAS Google Scholar
Anand, K., Pal, D. & Hilgenfeld, R. (2002). Acta Cryst. D58, 1722–1728. Web of Science CrossRef CAS IUCr Journals Google Scholar
Anderson, M. J., Hansen, C. L. & Quake, S. R. (2006). Proc. Natl Acad. Sci. USA, 103, 16746–16751. Web of Science CrossRef PubMed CAS Google Scholar
Aÿ, J., Götz, F., Borriss, R. & Heinemann, U. (1998). Proc. Natl Acad. Sci. USA, 95, 6613–6618. PubMed Google Scholar
Banayan, N. E., Loughlin, B. J., Singh, S., Forouhar, F., Lu, G., Wong, K. H., Neky,
M., Hunt, H. S., Bateman, L. B. Jr, Tamez, A., Handelman, S. K., Price, W. N. & Hunt,
J. F. (2024). Protein Sci. 33, e4898. CrossRef PubMed Google Scholar
Benvenuti, M. & Mangani, S. (2007). Nat. Protoc. 2, 1633–1651. Web of Science CrossRef PubMed CAS Google Scholar
Bergfors, T. M. (2009). Protein Crystallization. La Jolla: International University Line. Google Scholar
Broecker, J., Eger, B. T. & Ernst, O. P. (2017). Structure, 25, 384–392. CrossRef CAS PubMed Google Scholar
Budziszewski, G. R., Snell, M. E., Wright, T. R., Lynch, M. L. & Bowman, S. E. (2023).
J. Vis. Exp., e65211. Google Scholar
Caffrey, M. (2015). Acta Cryst. F71, 3–18. Web of Science CrossRef IUCr Journals Google Scholar
Carter, C. W. & Carter, C. W. (1979). J. Biol. Chem. 254, 12219–12223. CrossRef CAS PubMed Web of Science Google Scholar
Caspy, I., Tang, S., Bellini, D. & Gorrec, F. (2025). J. Appl. Cryst. 58, 383–391. CrossRef CAS IUCr Journals Google Scholar
Chayen, N. E. (1998). Acta Cryst. D54, 8–15. Web of Science CrossRef CAS IUCr Journals Google Scholar
Chayen, N. E., Shaw Stewart, P. D. & Blow, D. M. (1992). J. Cryst. Growth, 122, 176–180. CrossRef CAS Web of Science Google Scholar
Chayen, N. E., Shaw Stewart, P. D., Maeder, D. L. & Blow, D. M. (1990). J. Appl. Cryst. 23, 297–302. CrossRef CAS Web of Science IUCr Journals Google Scholar
Cherezov, V. (2011). Curr. Opin. Struct. Biol. 21, 559–566. Web of Science CrossRef CAS PubMed Google Scholar
Chun, E., Thompson, A. A., Liu, W., Roth, C. B., Griffith, M. T., Katritch, V., Kunken,
J., Xu, F., Cherezov, V., Hanson, M. A. & Stevens, R. C. (2012). Structure, 20, 967–976. Web of Science CrossRef CAS PubMed Google Scholar
Dale, G. E., Oefner, C. & D'Arcy, A. (2003). J. Struct. Biol. 142, 88–97. Web of Science CrossRef PubMed CAS Google Scholar
D'Arcy, A., Bergfors, T., Cowan-Jacob, S. W. & Marsh, M. (2014). Acta Cryst. F70, 1117–1126. Web of Science CrossRef IUCr Journals Google Scholar
D'Arcy, A., Elmore, C., Stihle, M. & Johnston, J. E. (1996). J. Cryst. Growth, 168, 175–180. CrossRef CAS Web of Science Google Scholar
Derewenda, Z. S. (2004). Structure, 12, 529–535. Web of Science CrossRef PubMed CAS Google Scholar
Derewenda, Z. S. & Vekilov, P. G. (2006). Acta Cryst. D62, 116–124. Web of Science CrossRef CAS IUCr Journals Google Scholar
Dumetz, A. C., Snellinger-O'Brien, A. M., Kaler, E. W. & Lenhoff, A. M. (2007). Protein Sci. 16, 1867–1877. Web of Science CrossRef PubMed CAS Google Scholar
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W. & Jhoti, H. (2016). Nat. Rev. Drug Discov. 15, 605–619. Web of Science CrossRef CAS PubMed Google Scholar
Faham, S. & Bowie, J. U. (2002). J. Mol. Biol. 316, 1–6. Web of Science CrossRef PubMed CAS Google Scholar
Finet, S., Vivarès, D., Bonneté, F. & Tardieu, A. (2003). Methods Enzymol. 368, 105–129. Web of Science CrossRef PubMed CAS Google Scholar
Frontana-Uribe, B. A. & Moreno, A. (2008). Cryst. Growth Des. 8, 4194–4199. CAS Google Scholar
Griffin, L. & Lawson, A. (2011). Clin. Exp. Immunol. 165, 285–291. Web of Science CrossRef CAS PubMed Google Scholar
Haupert, L. M. & Simpson, G. J. (2011). Methods, 55, 379–386. Web of Science CrossRef CAS PubMed Google Scholar
Hoeppner, A., Schmitt, L & Smits, S. H. J. (2013). Advanced Topics on Crystal Growth, edited by S. O. Ferreira, ch. 1. Rijeka: IntechOpen. Google Scholar
Hough, M. A. & Owen, R. L. (2021). Curr. Opin. Struct. Biol. 71, 232–238. Web of Science CrossRef CAS PubMed Google Scholar
Jancarik, J. & Kim, S.-H. (1991). J. Appl. Cryst. 24, 409–411. CrossRef CAS Web of Science IUCr Journals Google Scholar
Kantardjieff, K. A. & Rupp, B. (2004). Bioinformatics, 20, 2162–2168. Web of Science CrossRef PubMed CAS Google Scholar
Kern, J., Alonso-Mori, R., Tran, R., Hattne, J., Gildea, R. J., Echols, N., Glöckner,
C., Hellmich, J., Laksmono, H., Sierra, R. G., Lassalle-Kaiser, B., Koroidov, S.,
Lampe, A., Han, G., Gul, S., Difiore, D., Milathianaki, D., Fry, A. R., Miahnahri,
A., Schafer, D. W., Messerschmidt, M., Seibert, M. M., Koglin, J. E., Sokaras, D.,
Weng, T. C., Sellberg, J., Latimer, M. J., Grosse-Kunstleve, R. W., Zwart, P. H.,
White, W. E., Glatzel, P., Adams, P. D., Bogan, M. J., Williams, G. J., Boutet, S.,
Messinger, J., Zouni, A., Sauter, N. K., Yachandra, V. K., Bergmann, U. & Yano, J.
(2013). Science, 340, 491–495. Web of Science CrossRef CAS PubMed Google Scholar
Kuge, M., Fujii, Y., Shimizu, T., Hakoshima, T., Hirose, F. & Matsukage, A. (1997).
Protein Sci. 6, 1783–1786. CrossRef CAS PubMed Google Scholar
Kupitz, C., Basu, S., Grotjohann, I., Fromme, R., Zatsepin, N. A., Rendek, K. N.,
Hunter, M. S., Shoeman, R. L., White, T. A., Wang, D., James, D., Yang, J. H., Cobb,
D. E., Reeder, B., Sierra, R. G., Liu, H., Barty, A., Aquila, A. L., Deponte, D.,
Kirian, R. A., Bari, S., Bergkamp, J. J., Beyerlein, K. R., Bogan, M. J., Caleman,
C., Chao, T. C., Conrad, C. E., Davis, K. M., Fleckenstein, H., Galli, L., Hau-Riege,
S. P., Kassemeyer, S., Laksmono, H., Liang, M., Lomb, L., Marchesini, S., Martin,
A. V., Messerschmidt, M., Milathianaki, D., Nass, K., Ros, A., Roy-Chowdhury, S.,
Schmidt, K., Seibert, M., Steinbrener, J., Stellato, F., Yan, L., Yoon, C., Moore,
T. A., Moore, A. L., Pushkar, Y., Williams, G. J., Boutet, S., Doak, R. B., Weierstall,
U., Frank, M., Chapman, H. N., Spence, J. C. H, & Fromme, P. (2014). Nature, 513, 261–265. Web of Science CrossRef CAS PubMed Google Scholar
Kupitz, C., Grotjohann, I., Conrad, C. E., Roy-Chowdhury, S., Fromme, R. & Fromme,
P. (2014). Phil. Trans. R. Soc. B, 369, 20130316. Web of Science CrossRef PubMed Google Scholar
Landau, E. M. & Rosenbusch, J. P. (1996). Proc. Natl Acad. Sci. USA, 93, 14532–14535. CrossRef CAS PubMed Web of Science Google Scholar
Liebau, J., Laatsch, B. F., Rusnak, J., Gunderson, K., Finke, B., Bargender, K., Narkiewicz-Jodko,
A., Weeks, K., Williams, M. T., Shulgina, I., Musier-Forsyth, K., Bhattacharyya, S.
& Hati, S. (2024). Biochemistry, 63, 1621–1635. CrossRef CAS PubMed Google Scholar
Lieberman, R. L., Culver, J. A., Entzminger, K. C., Pai, J. C. & Maynard, J. A. (2011).
Methods, 55, 293–302. Web of Science CrossRef CAS PubMed Google Scholar
Lin, G., Barnes, C. O., Weiss, S., Dutagaci, B., Qiu, C., Feig, M., Song, J., Lyubimov,
A., Cohen, A. E., Kaplan, C. D. & Calero, G. (2024). Proc. Natl Acad. Sci. USA, 121, e2318527121. CrossRef PubMed Google Scholar
Liu, B., Luna, V. M., Chen, Y., Stout, C. D. & Fee, J. A. (2007). Acta Cryst. F63, 1029–1034. Web of Science CrossRef IUCr Journals Google Scholar
Liu, Y., Hou, H., Li, J., Cheng, Q.-D., Zhang, X., Zeng, X.-B., Fiaz, A., Wang, B.,
Zhang, C.-Y., Lu, Q.-Q. & Yin, D.-C. (2020). Cryst. Growth Des. 20, 1694–1705. CrossRef CAS Google Scholar
Luft, J. R., Wolfley, J., Jurisica, I., Glasgow, J., Fortier, S. & DeTitta, G. T.
(2001). J. Cryst. Growth, 232, 591–595. Web of Science CrossRef CAS Google Scholar
Lynch, M. L., Dudek, M. F. & Bowman, S. E. J. (2020). Patterns, 1, 100024. Web of Science CrossRef PubMed Google Scholar
Lynch, M. L., Snell, M. E., Potter, S. A., Snell, E. H. & Bowman, S. E. J. (2023).
Acta Cryst. D79, 198–205. Web of Science CrossRef IUCr Journals Google Scholar
Mazzorana, M., Shotton, E. J. & Hall, D. R. (2020). Drug. Discov. Today Technol. 37, 83–92. CrossRef PubMed Google Scholar
McPherson, A. (2001). Protein Sci. 10, 418–422. Web of Science CrossRef PubMed CAS Google Scholar
McPherson, A. & Cudney, B. (2006). J. Struct. Biol. 156, 387–406. Web of Science CrossRef PubMed CAS Google Scholar
McPherson, A. & Gavira, J. A. (2014). Acta Cryst. F70, 2–20. Web of Science CrossRef CAS IUCr Journals Google Scholar
Mikolajek, H., Sanchez-Weatherby, J., Sandy, J., Gildea, R. J., Campeotto, I., Cheruvara,
H., Clarke, J. D., Foster, T., Fujii, S., Paulsen, I. T., Shah, B. S. & Hough, M.
A. (2023). IUCrJ, 10, 420–429. Web of Science CrossRef CAS PubMed IUCr Journals Google Scholar
Muenks, A., Zepeda, S., Zhou, G., Veesler, D. & DiMaio, F. (2023). Nat. Commun. 14, 1164. CrossRef PubMed Google Scholar
Murray, C. W. & Rees, D. C. (2009). Nat. Chem. 1, 187–192. Web of Science CrossRef CAS PubMed Google Scholar
Nannenga, B. L. & Gonen, T. (2019). Nat. Methods, 16, 369–379. Web of Science CrossRef CAS PubMed Google Scholar
Nawarathnage, S., Tseng, Y. J., Soleimani, S., Smith, T., Pedroza Romo, M. J., Abiodun,
W. O., Egbert, C. M., Madhusanka, D., Bunn, D., Woods, B., Tsubaki, E., Stewart, C.,
Brown, S., Doukov, T., Andersen, J. L. & Moody, J. D. (2023). Structure, 31, 1589–1603. CrossRef CAS PubMed Google Scholar
Nikolaev, M., Round, E., Gushchin, I., Polovinkin, V., Balandin, T., Kuzmichev, P.,
Shevchenko, V., Borshchevskiy, V., Kuklin, A., Round, A., Bernhard, F., Willbold,
D., Büldt, G. & Gordeliy, V. (2017). Cryst. Growth Des. 17, 945–948. Web of Science CrossRef CAS Google Scholar
Pearson, A. R. & Mehrabi, P. (2020). Curr. Opin. Struct. Biol. 65, 168–174. Web of Science CrossRef CAS PubMed Google Scholar
Rastogi, H. & Chowdhury, P. K. (2021). Biochim. Biophys. Acta, 1869, 140699. CrossRef Google Scholar
Ray, W. J. & Puvathingal, J. (1986). J. Biol. Chem. 261, 11544–11549. CrossRef CAS PubMed Google Scholar
Rosa, N., Ristic, M., Thorburn, L., Abrahams, G. J., Marshall, B., Watkins, C. J.,
Kruger, A., Khassapov, A. & Newman, J. (2020). Crystals, 10, 95. Web of Science CrossRef Google Scholar
Rubin, E., Owen, C. & Stojanoff, V. (2017). Crystals, 7, 206. CrossRef Google Scholar
Sandy, J., Mikolajek, H., Thompson, A. J., Sanchez-Weatherby, J. & Hough, M. A. (2024).
J. Vis. Exp., e65964. Google Scholar
Saul, F. A., Vulliez-le Normand, B., Lema, F. & Bentley, G. A. (1998). J. Mol. Biol. 280, 185–192. Web of Science CrossRef CAS PubMed Google Scholar
Shaw Stewart, P. D., Kolek, S. A., Briggs, R. A., Chayen, N. E. & Baldock, P. F. M.
(2011). Cryst. Growth Des. 11, 3432–3441. Web of Science CrossRef CAS Google Scholar
Shelby, M. L., Gilbile, D., Grant, T. D., Bauer, W. J., Segelke, B., He, W., Evans,
A. C., Crespo, N., Fischer, P., Pakendorf, T., Hennicke, V., Hunter, M. S., Batyuk,
A., Barthelmess, M., Meents, A., Kuhl, T. L., Frank, M. & Coleman, M. A. (2020). Crystals, 10, 886. CrossRef PubMed Google Scholar
Shoeman, R. L., Hartmann, E. & Schlichting, I. (2023). Nat. Protoc. 18, 854–882. Web of Science CrossRef CAS PubMed Google Scholar
Slabinski, L., Jaroszewski, L., Rychlewski, L., Wilson, I. A., Lesley, S. A. & Godzik,
A. (2007). Bioinformatics, 23, 3403–3405. Web of Science CrossRef PubMed CAS Google Scholar
Smith, N., Dasgupta, M., Wych, D. C., Dolamore, C., Sierra, R. G., Lisova, S., Marchany-Rivera,
D., Cohen, A. E., Boutet, S. & Hunter, M. S. (2024). Sci. Adv. 10, eadk7201. CrossRef PubMed Google Scholar
Smyth, D. R., Mrozkiewicz, M. K., McGrath, W. J., Listwan, P. & Kobe, B. (2003). Protein Sci. 12, 1313–1322. Web of Science CrossRef PubMed CAS Google Scholar
Stegmann, D. P., Steuber, J., Fritz, G., Wojdyla, J. A. & Sharpe, M. E. (2023). Methods Enzymol. 690, 235–284. CrossRef CAS PubMed Google Scholar
Taleb, M., Didierjean, C., Jelsch, C., Mangeot, J. P., Capelle, B. & Aubry, A. (1999).
J. Cryst. Growth, 200, 575–582. Web of Science CrossRef CAS Google Scholar
Tamura, R., Oi, R., Akashi, S., Kaneko, M. K., Kato, Y. & Nogi, T. (2019). Protein Sci. 28, 823–836. Web of Science CrossRef CAS PubMed Google Scholar
Thomas, D., Rob, A. & Rice, D. (1989). Protein Eng. Des. Sel. 2, 489–491. CrossRef CAS Google Scholar
Warren, A. J., Trincao, J., Crawshaw, A. D., Beale, E. V., Duller, G., Stallwood,
A., Lunnon, M., Littlewood, R., Prescott, A., Foster, A., Smith, N., Rehm, G., Gayadeen,
S., Bloomer, C., Alianelli, L., Laundy, D., Sutter, J., Cahill, L. & Evans, G. (2024).
J. Synchrotron Rad. 31, 1593–1608. Web of Science CrossRef CAS IUCr Journals Google Scholar
Zeppezauer, M. (1971). Methods Enzymol. 22, 253–266. CrossRef Google Scholar
Zheng, H., Hou, J., Zimmerman, M. D., Wlodawer, A. & Minor, W. (2014). Exp. Opin. Drug. Discov. 9, 125–137. Web of Science CrossRef CAS Google Scholar
Zou, Y., Weis, W. I. & Kobilka, B. K. (2012). PLoS One, 7, e46039. Web of Science CrossRef PubMed Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.